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Background: The number of patients under antiplatelet therapy (APT) continues to raise as current recommenda-
tions foster this practice. Although some recommendations to manage this treatment during oral surgery proce-
dures exist, these have methodological shortcomings that preclude them from being conclusive.
Material and Methods: A systematic review and meta-analysis of the best current evidence was carried out; The 
Cochrane Library, EMBASE and MEDLINE databases were searched for Randomized Controlled Trials (RCT) 
concerning patients undergoing oral surgery with APT, other relevant sources were searched manually. 
Results: 5 RCTs met the Inclusion criteria. No clear tendency was observed (RR= 0.97 CI 95%: 0,41–2,34; p=0,09; 
I2= 51%), moreover, they weren’t clinically significant. 
Conclusions: According to these findings and as bleeding is a manageable complication it seems unreasonable to 
undermine the APT, putting the patient in danger of a thrombotic event and its high inherent morbidity, which isn’t 
comparable in severity and manageability to the former.”





Blood flow obstruction by a clot may cause ischemia 
and organ infarction. Thrombus formation is produced 
as consequence of vascular injuries, activation of the 
clotting process and blood flow disruption, this can hap-
pen at venous or arterial level. In arterial thrombosis the 
main etiologic factors are platelet activation and injuries 
to the arterial wall such as atheromatous plaques pro-
ducing platelet rich thrombi. Blood Stasis and clotting 
are the main factors in venous thrombosis, producing 
thrombi rich in fibrin and erythrocytes (1).
Atherothrombosis, i.e., thrombus formation over an 
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already present atherosclerotic plaque, causes cardio-
vascular diseases (2). The most important are stroke, 
coronary disease and peripheral vascular disease (3). 
Nowadays, these are the top mortality causes worldwide 
(4-6). The World Health Organization has declared that 
in the year 2030 approximately 23.6 million people will 
die every year due to cardiovascular complications (2,3).
Therefore, antiplatelet therapy (APT) for a number of 
thrombotic conditions has increased in the last years in 
primary prevention (prophylactic) and secondary pre-
vention (1). 
Currently available antiplatelet agents include acetylsali-
cylic acid (aspirin), thienopyridines (clopidogrel, ticlopi-
dine) IIb/IIIa platelet receptor inhibitors and phosphodi-
esterase inhibitors, which act upon the different phases 
of activation (2). The protective effects of APT against 
cardiovascular disease have been clearly and concisely 
demonstrated throughout the groups at higher risk (2).
Treatments carried out in the oral cavity, especially those 
that may cause blood extravasation, imply a high risk 
of perioperative bleeding in patients with an altered he-
mostasis (7,8). Although a 90% of minor postoperative 
bleedings are due to local factors such as the anatomical 
situation, excessive surgical trauma and/or not following 
postoperative indications, most of the severe bleedings 
are related with systemically alterations that compromise 
the primary or secondary hemostasis mechanisms (7).
In the light of these issues it must be considered whether 
if it is necessary to halt or modify the treatment in at-
tention of the higher risk of a non-manageable event of 
bleeding, peri or postoperatively (9) considering that 
even a transitory interruption of this kind of medica-
tion may lead to a thrombotic event with a worst final 
outcome (10). 
There are a number of published articles in the medi-
cal literature intended to underpin the clinical decisions 
regarding this issue, however, most of them are meth-
odologically flawed, making it hard to properly support 
such decisions. Therefore, it is necessary to identify, as-
sess and synthetize all the evidence available through a 
systematic method that could clarify and improve deci-
sion making, defining if it is necessary to modify APT 
in patients undergoing oral surgery in consideration of 
the known risks and benefits. 
With this goal, a systematic review of the literature was 
carried out. The PICO question was: Patients: Under-
going oral surgery under Antiplatelet Therapy (APT). 
Intervention: Suspension of APT. Comparison: Main-
tained APT. Outcome: Risk of perioperative bleeding.
Material and Methods
A systematic review of the literature and a meta-analy-
sis was conducted. In August of 2017, a structured and 
systematic search for randomized controlled trials re-
garding APT and oral surgery was made.
Inclusion: Randomized controlled clinical trials regard-
ing bleeding following oral surgery with suspension or 
maintenance of anti-platelet therapy.
Exclusion criteria: Non-randomized or non-controlled 
clinical trials, observational studies, narrative reviews, 
case reports and letters to the editor, outcome or com-
parison analyzed didn t́ match the inclusion criteria.
The databases searched were THE COCHRANE LI-
BRARY, MEDLINE and EMBASE (annex 1), Also, 
a search was carried out in databases of clinical tri-
als such as: Current Controlled Trials (http://www.
controlledtrials.com/), ClinicalTrials.gov (http://www.
clinicaltrials.gov/), WHO International Clinical Trials 
Registry Platform (ICTRP) (http://www.who.int/ictrp/
en/). The reference list of the articles included was also 
searched for articles eligible for this review. A search 
was also conducted in Google Scholar in order to detect 
grey literature. In journals of the specialty, given the 
belated indexation of articles in databases, the issues 
published in the last 6 months were also reviewed, the 
reviewed journals were: Journal of Oral and Maxillofa-
cial Surgery; International Journal of Oral and Maxil-
lofacial Surgery; British Journal of Oral and Maxillo-
facial Surgery; Journal of Craniofacial Surgery; Head 
& Neck: Journal for the Sciences & Specialties of the 
Head and Neck. Finally, the last 5 years of online sum-
maries from the American Association of Oral and 
Maxillofacial Surgeons and International Association 
of Dental Research meetings were manually searched. 
All the potentially relevant articles found were num-
bered, afterwards, they were filtered based on their title 
and summary. This process was performed by 2 review-
ers independently, following the inclusion and exclusion 
criteria previously determined, being these widely in-
clusive overall. 
Subsequently, all the articles selected were submitted to 
a full-text appraisal. In the same fashion as the previ-
ous stage of selection described, 2 independent review-
ers carried out the assessment in accordance with the 
inclusion and exclusion criteria previously determined. 
The inter-examiner agreement was evaluated with the 
kappa index (κ= 0,691). Any disagreement was sorted 
out by consensus or, when it wasn t́ possible, by a third 
reviewer that acted as arbiter. 
A flowchart is included (Fig. 1), following the recom-
mendations of the PRISMA Statement (11), in order to 
illustrate the results of the study selection for this review.
DATA EXTRACTION: In a data extraction form, 2 re-
viewers independently handled the data aided by a Mi-
crosoft ® Excel Office 2016 template designed with this 
purpose. Disagreements were checked by both reviewers 
and when consensus couldn t́ be reached a third reviewer 
acted as arbiter. The form registered the following: (i) 
Information regarding the study characteristics: number 
of patients included, number of intervention and control 
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groups, intervention of interest, control interventions and 
counter interventions, (ii) Information regarding the re-
sults: bleeding definition, (iii) Bias information: selection 
bias, performance bias, detection bias, etc. 
RISK OF BIAS ASSESSMENT: The Risk of Bias of 
the included articles was assessed using the Cochrane 
Collaboration ś Risk of Bias Tool (12). The assessment 
was made by 2 reviewers independently reading the 
full-text of the included articles. Disagreement was dis-
cussed and agreement was reached in order to classify 
the articles in either high, low or unclear risk of bias. It 
has already been demonstrated that author blinding or 
study affiliation does not influence results assessment 
(13), therefore, the reviewers weren t́ blinded to this 
data. Results were presented following the PRISMA 
recommendations (Figs. 2a,b).
The following effect measurements for the treatment 
were used to assess the outcome for each study: Bleed-
ing: Relative Risk (RR) was calculated for the effects 
of treatment (dichotomous outcomes), with a confidence 
interval of 95% or differences of the risks at their confi-
dence intervals at 95%. 
STUDIES´S HETEROGENEITY ASSESSMENT: The 
chi-square test was used in order to determine the pres-
ence of statistical heterogeneity, a 0,1 significance level 
was used. Quantification of the inconsistency was made 
by the statistical I2 test, following the Cochrane recom-
mendations (14). Clinical heterogeneity was assessed 
considering the patient ś characteristics, environment 
and intervention, consulted with experts. Method-
ological heterogeneity was assessed by the Risk of Bias 
Tool ś domains (14).
DATA SYNTHESIS: A narrative description of the in-
cluded trials ś characteristics is provided. Also, a meta-
analysis of the included data results generated by the 
RevMan 5.1 software is presented. In comparisons were 
no clinically apparent heterogeneity was found and the 
I² value is 40% or less, a fixed effects model was used. 
When clinical heterogeneity was present and the I² value 
is more than 40%, a random effects model was used (15).
SENSITIVITY ASSESSMENT: Given that allocation 
concealment and blinding was the most critical bias do-
main in this review, the trials were classified as at high 
risk of bias, if the assignment concealment domain and 
two more domains had high risk of bias. The same cri-
teria was applied to classify an essay as having unclear 
risk of bias. We included all studies, in spite of the high 
risk of bias. Because the GRADE tool (16) is used to 
define the quality of the evidence allowing us to incor-
porate every study in the review.
Fig. 1. Flowchart depicting study selection.
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Fig. 2. a) Summary of Risk of Bias: Assessment of the reviewers of the Risk of Bias in each domain for 
each study. b) Risk of Bias Chart: Assessment of the reviewers for each domain of each article, shown 
as percentages.
QUALITY OF EVIDENCE ASSESSMENT: The qual-
ity of evidence for the result (bleeding) was classified 
using the GRADE Guidelines, accordingly, an evidence 
profile was included in Table 1 (16). 
Results
The electronic search brought 232 references and the 
manual search added 2 more published articles. After 
the exclusion of duplicates 223 articles were submit-
ted for screening of their titles and summaries. 20 ar-
ticles were deemed potentially relevant. Once the full 
text was analyzed, a total of 5 articles were included 
in this review: Gaspar, 1999 (17); Ardekian, 2000 (18); 
Medeiros, 2011 (19); Varghese 2015 (20) and Sadha-
sivam 2016 (21) (Table 2, 2 continue: Characteristics 
of included studies). Of the 20 articles in which its full 
text was reviewed, 15 were excluded from this review 
as they didn t́ meet the inclusion criteria (Table 3, 3 con-
tinue). From the included studies, 2 were conducted in 
Israel (17,18), 1 in Brazil (19), 2 in India (20,21). Only 
one specifies in which setting it was conducted, being 
that, a medical center (18). 
The full number of patients included in the studies was 
542, this ranged from 39 (18) to 200 (21). Demographi-
cal data was reported in the 3 studies, male participants 
were in higher proportion than females and the mean 
age of the participants was between 58 years (19) and 
64 years (18).
The type and number of oral surgery procedures was 
variable among the studies, among these were included, 
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Patient : Patients undergoing oral surgery                                                                                                                                                                                                                                                           
Configuration: Systematic review                                                                                                                                                                                                                                                                                                     
Intervention : APT Suspension                                                                                                                                                                                                                                                                                                           
Comparation: Unaltered APT 
Result  






Anticipated absolute effects (95% CI)  Certainty  
Without 
suspension 
With suspension Diference 
Severe Bleeding 








8,8.0%  8,5% 
(3.6 to 20.5)  
0,3% less  




Risk in the intervention group (and confidence interval at 95%) based on the presumed risk in the comparison 
group and relative effect of the intervention (and confidence interval at 95%).  
CI: confidence interval; RR: Risk ratio  
GRADE Working Group degrees of evidence 
High certainty: We are very sure that the estimation of effect is close to the true effect.                                                                                                                                                                                                                                  
Moderate certainty: We are moderately confident in the effect estimation: it is likely that the true effect is close 
of the effect estimation, but there is a chance that it is substantially different. 
Low certainty: Our confidence in the estimation is limited: The true effect may be substantially different from the 
estimated effect.                                                                                                                                            Very low 
certainty: We have very little confidence in the estimation of the effect: it is likely that the true effect is 
substantially different to the estimation of the effect. 
	
Table 1. GRADE Evidence Profile for APT suspension compared with unaltered APT in patients undergoing oral 
surgery.
Explanation:
a. Serious problems in bias risk assessment due to unclear risk of bias in every study at randomized generation of the se-
quence, allocation concealment and blinding results assessment. 
b. Serious problems of imprecision: The confidence interval at 95% suggests either great benefit or great detriment. 
Events are few (n=52). 
dental extractions only (19-21), single or multiple. The 
other studies comprised single tooth extractions with or 
without alveoloplasty (18) as well as other minor oral 
surgery procedures such as apicoectomies and peri-
odontal surgery (18). 
The inclusion criteria for participants were reported in 
three studies (17-19) and was not informed in two stud-
ies (20,21). All of them included patients in APT with 
acetylsalicylic acid. Exclusion criteria was not informed 
in two of these (18,21). The exclusion criteria in the oth-
er three studies are concomitant treatment with oral an-
ticoagulation drugs, alcoholism, liver disease, impacted 
tooth and blood dyscrasias (18-20). 
All the trials had parallel groups and the effects of main-
taining the APT in contrast with suspension of the for-
mer 7 days and 3-5 days prior to the procedure (17-21) 
Five of the included studies evaluated intense bleeding 
events. All had the patient monitored and evaluated by 
the treating professional during the first 24 hours fol-
lowing the procedure. Three studies reported a follow-
up period of 7 days (17-21).
There is no universally accepted standardized defini-
tion of bleeding in patients undergoing oral surgery, 
therefore the outcome of interest was described by 3 of 
the studies as intraoperative bleeding, being determined 
by subtraction of the irrigation fluid from the blood ac-
cumulated in the suction flask (18,19,21). The result in 
these studies was reported as intense bleeding.
No study reported the occurrence of stroke, an ischemic 
cardiac event, nor quality of life assessment following 
the intervention. 
RISK OF BIAS: The risk of bias assessment is displayed 
in Figure 2. No study was classified in every domain as 
low risk of bias. 
The domain considered as at low risk of bias was the 
selective report of results, and the incomplete report of 
data (Fig. 2).  
Only two studies gave details regarding the randomized 
sequence generation; therefore, the other three were 
classified as studies with unclear risk of bias in this do-
main. 
No study reported information regarding the allocation 
concealment, therefore they were classified as studies 
with an unclear risk of bias in this domain. 
This domain was evaluated in 2 areas, blinding of the 
patients and personnel (performance bias) and blinding 
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Table 2. Characteristics of the Included Studies. APT= Anti-Platelet Therapy; ASA= Acetyl Salicylic Acid; N= Number of patients; (+) = Con-



























Not reported 50 (1) +ASA 
(28 patients)              
(2) -ASA 7 
days prior, 











Not reported 1 day
Ardekian 
2000 (18)
APT w/ ASA 











tion <100 gr/L) or 
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39 (1) +ASA 
(19 patients)        
(2) -ASA 7 
days prior 1 
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63 (1) APT thera-
py suspended 








(2) patients did 
not have their 
APT therapy 
suspended
at any point 



















Liver disease, blood 
pressure >140/90 
mmHg, bleeding or 
clotting 
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tooth, uncontrolled 
systemic diseases














Sutured with 3–0 
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5 days














ued APT 3–5 
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Not reported 1 week
Table 2 continue. Characteristics of the Included Studies. APT= Anti-Platelet Therapy; ASA= Acetyl Salicylic Acid; N= Number of patients; 
(+) = Continues APT; (-) =Suspended APT; OACT= Oral Anti-Coagulation Treatment.
Study N Intervention Oral surgery 
procedures
Primary outcome Co interventions Reason for exclusion
Pawlak 1978 43 (1) ASA 1 day before 
or 1 day after (20 
patients)
(2) Acetaminophen 




Not reported Patients without APT. 




40 (1) Healthy: 2 gr de 
ASA after 1st surgery 
and placebo after 2nd 
surgery (20 patients)
(2) Healthy: 4 g de 
ASA after 1st surgery 





Not reported Post-surgical ASA for 
pain and inflammation
Hemelik 2006 317 (1) ASA (65 patients)




Suture CS. Healthy control 
group. No APT 
suspension
Brennan 2008 36 (1) ASA 2 days before 
and after (17 patients)        
(2) Placebo days before 
and after (19 patients)
Extractions Intraoperative 
bleeding time
Not reported Not under regular APT
Krishnan 
2008
82 (1) (-) ASA 1-10 days 
before (25 patients)                 
(2) (+) ASA 
(32 patients)                                         




bleeding after 30 
mins with gauze 
compression
Not reported Outcome of interest not 
reported
Lillis 2011 643 (1) ASA (42 patients)
(2) Clopidogrel (36 
patients)
(3) ASA + Clopidogrel 
(33 patients)
(4) Healthy (532 
patients)
Extractions Postoperative 
bleeding after 30 
mins of gauze 
compression
Not reported CS. Healthy control 
group. No experimental 
APT Suspension
Park 2012 200 (1) Under APT (100 
patients)




Not reported CS. Healthy control 
group. No experimental 
APT suspension
Table 3. Characteristics of excluded studies and reasons for exclusion, following full-text screening. APT= Antiplatelet Therapy; ASA= Acetyl-
salicylic Acid; N= number of patients; (+)=  continues APT; (-)= APT suspension. CS= Cohort Study.
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Girotra 2013 1121 (1) Healthy (575 pa-
tients)
(2) Under APT with 
ASS and/or Clopido-





bleeding after 30 
mins of gauze 
compression
Suture with silk 
3-0
CS. Healthy control 
group. No experimental 
APT Suspension
Wang 2013 600 (1) (-) ASA 1 month 
before (100 patients) 
(1.1) Healthy (200 
patients)
(2) (+) ASA (100 pa-
tients)
(2.1) Healthy (200 
patients)
Extractions Postoperative 
bleeding at 5, 10, 
30 and 40 mins.
Not reported CS. Healthy control 
group. 
Bajkin 2014 265 (1) APT dual (43 
patients) 








Colagen sponge CS. Healthy control 
group. No experimental 
APT suspension.
Gröbe 2015 405 (1) Healthy (281








bleeding at day 1, 






Omar 2015 68 (1) ASA (25 patients 
(2) Clopidogrel (12 
patients) (3) ASA + 
Clopidogrel (9 
patients) (4) w/o APT 
(22 patients)







Not reported Retrospective, C-C 
Study, Outcome of inter-
est not reported.
Dészi 2015 129 (1) Clopidogrel + ASA 
(63 patients)






VC. Gauze local 
compression or 
sutures.
No APT suspension, 
Compares APT schemes. 
Presence of cointerven-
tions
Lu 2016 1271 (1) Healthy (1088 
patients)
(2) AAS y/o 
Clopidogrel (183 
patients)
Extractions 10 mins after, 
postoperative 
bleeding w gauze 
compression




114 (1) ASA y Clopidogrel 
(64 patients)
(2) Healthy (50 
patients)
Extractions Postoperative 
bleeding 30 mins. 
After gauze 
compression
Not reported CS. Healthy control 
group. No experimental 
APT suspension.
Table 3 continue. Characteristics of excluded studies and reasons for exclusion, following full-text screening. APT= Antiplatelet Therapy; 
ASA= Acetylsalicylic Acid; N= number of patients; (+)=  continues APT; (-)= APT suspension. CS= Cohort Study.
of the outcome assessors (detection bias). Regarding 
performance bias, only 1 study describes blinding (19). 
No study gave information about the assessor ś blind-
ing, therefore they were classified as unclear risk of bias 
in this domain.  
Five studies were classified as low risk of bias, as the 
criteria for intraoperative bleeding assessment (17-21).
Two studies had co-interventions, considered as a high 
risk in other sources of bias. These were use of suture, 
biological adhesive and local anesthetic 3% percent.
Outcome: Perioperative bleeding
The global estimator for intense bleeding was reported for 
patients undergoing oral surgery in a group that suspended 
the APT in contrast with a group in which no suspension 
was indicated, the findings are in terms of relative risk 
(RR=0,97); with a 95% confidence interval (CI), ranging 
from 0,41 to 2.34. Heterogeneity: Chi square test= 8.16; 
p=0,09 and the Inconsistence test I2=51%. As there was 
apparent clinical heterogeneity, having an I² value higher 
than 51%, a random effect model was applied.
META-ANALYSIS: The meta-analysis is shown in Fig-
ure 3.
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Fig. 3. Forest Plot: Each square represents a punctual estimator (Relative Risk) for each study, 
while the diamond at its mid-section, represents the Global Estimator (0,97). The horizontal 
lines that cross the boxes illustrate the magnitude of the confidence interval at 95%. The dia-
mond width serves the same purpose (0,41-2,34). The vertical line depicts the line of no-effect, 
depicting a neutral RR. The horizontal spacing between a box and the vertical line shows the 
difference between the experimental group and the control in relationship to a neutral effect. 
The size of each square depicts the weight of each study, indicating the relevance of each one 
in the global estimation.
EVIDENCE QUALITY ASSESSMENT: The protec-
tive effect of APT suspension over perioperative bleed-
ing in patients undergoing minor oral surgery proce-
dures was qualified as low-quality evidence according 
to the GRADE domains (Table 1).
Discussion
The fear of a postoperative hemorrhagic event is well 
known in medical and dental practice. Fortunately, mi-
nor oral surgery jeopardizes anatomical sites that favor 
hemostatic control. These sites are frequently surround-
ed by bone tissue, meaning that there more possible ar-
eas over which pressure can be applied as well as other 
hemostatic measures, also, there is usually less soft tis-
sue that could generate bleeding, although irrigation is 
vast in this area. Moreover, the oral cavity is easy to 
supervise for the patient as well as the clinician, which 
enables early detection and opportune treatment of any 
possible complication (22). 
Likewise, diverse studies regard postoperative bleed-
ing cases mostly manageable with routinary hemostatic 
measures, such as pressure with a gauze, hemostatic 
material application, sutures with or without pro hemo-
static agents like tranexamic acid (40); Namely, it has 
been reported that the incidence postoperative bleeding 
that cannot be managed by these measures varies from 
0 to 3,5% (23,24).
In the last decades, APT prevalence has grown consid-
erably and is ever more frequent given the increased 
number of patients at risk of developing pathological 
entity related to a thrombotic event, as well as the num-
ber of cardiac surgeries involving prosthetic valves or 
coronary stents (25,26). 
The main risk of APT in the patient to be submitted to 
a surgical procedure is the risk of developing an uncon-
trollable hemorrhagic event.
It is essential to recommend and take clinical decisions 
before a patient in APT, to consider the consequences 
of possible hemorrhagic events during surgery bearing 
in mind the possible consequences of discontinuing the 
APT. Kearon and Hirsh observed in a comparative study 
approximately 20% of the cases of arterial thromboem-
bolism are fatal and a 40% result in permanent disabil-
ity (27). Another study reports that premature dual APT 
interruption is the leading cause of late thrombosis in 
patients submitted to angioplasty and stent installment 
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(28). Furthermore, there are over 50.000 of patients 
where aspirin cessation is associated with a threefold 
risk of developing cardiac events (29). 
In this scenario, considering the toll that thrombotic 
events carry over a patient ś health, it would be reason-
able to think of performing a surgical intervention with-
out alteration nor suspension of the antiplatelet therapy, 
provided that it wouldn t́ represent a significant risk of 
hemorrhagic complications. The purpose of this review 
is to determine if the APT is to be suspended, once 
thrombotic and hemorrhagic events are considered. 
In this systematic review it is evident, regarding the risk 
of bias, that none of the studies included described in a 
sufficiently clear manner the domains presented in the 
assessment tool, as to be classified as a study with a low 
risk of bias. On the other hand, after carrying out the 
meta-analysis, it could be seen that the included stud-
ies elicit a heterogeneity level of I2=51% with a non-sig-
nificant p value (p=0,09), however, as not every aspect 
needed to protect the methodological quality of the clin-
ical trials is explicated, it is not possible to presume that 
such methods were in fact employed in order to control 
the risk of bias, which compromises the precision of the 
results. This is why a random effect model was used in 
this case.
Individual results of each study are not sufficiently 
strong such as to favor APT suspension before oral 
procedures, because the confidence intervals of the in-
cluded studies are too wide, showing unprecise results 
to the point in which all of them cross the no-effect line. 
In addition, the risk of bias is high among the studies as 
a whole, ergo, these results are not clinically nor statisti-
cally significant.
Regarding the global estimator obtained from the meta-
analysis, it is observed that it does not favor suspension 
or maintenance of the APT in order to avoid intense 
intraoperative bleeding furthermore, the resultant con-
fidence interval crosses the neutral result line (RR=1), 
hence it is not clinically significant.
A point worthy of discussion is the definition of a bleed-
ing event. There is no consensus to define and measure 
bleeding after an oral surgery procedure in patient un-
der APT (30). Lockhart (31), suggested that an event of 
bleeding is considered significant if it meets 1 of 4 cri-
teria: bleeding that continues after 12 hours, that forces 
the patient to call or to head back to the office or an ur-
gency service, that results in the development of a con-
siderable hematoma or ecchymosis in the oral soft tis-
sues or, that requires blood transfusion (31). None of the 
studies included in this review reported such an event. 
For this systematic review the information available in 
the literature regarding invasive oral procedures con-
ducted in patients under APT was appraised. And only 
5 studies were found eligible in accordance with the 
inclusion criteria, nonetheless, there is a vast number 
of observational studies that in spite of not answering 
to the question posed in this review, render relevant 
knowledge to the topic. The scarcity of randomized 
clinical trials may well be attributed to the ethical di-
lemma generated by the possibility that patients, that 
have no indication to be enrolled in a trial, could be as-
signed to an intervention that puts them at risk of major 
adverse outcomes. 
It is important to note that only one of the included stud-
ies in this review considered patients under dual APT 
(21), therefore the results mainly portray the effects of 
ASA suspension. It is possible to conclude for these pa-
tients that the currently available evidence is not suf-
ficient to settle that the suspension of the APT leads to 
a beneficial effect over hemorrhagic events prevention. 
Given the available methods at disposal for periopera-
tive bleeding control, it would be advisable to keep the 
APT unaltered in attention to the associated risks of its 
interruption and foreseeable consequences.
There is even less existent evidence relative risk of 
bleeding with other drug than aspirin or dual APT 
(32,33). Dézsi (10), described an increased bleeding 
time in patients under dual APT with clopidogrel or 
prasugrel, in contrast with the patients under aspirin 
monotherapy (10). What is more, it has been reported 
that patients with combined anticlotting drugs and as-
pirin elicit an increased risk of suffering postoperative 
complications (33). Accordingly, the management of 
this patients requires additional considerations. 
The present systematic review exhibits limitations re-
garding the number and quality of the included studies. 
Studies with a bigger sample size and better design are 
necessary in the future. This encompasses, better meth-
odological quality in order to reduce the risk of bias, 
elimination of confounding variables and a clear defini-
tion of the parameters required to evaluate hemorrhagic 
events, so as to obtain results with broad clinical appli-
cations, allowing the evidence to effectively underpin 
clinical practice.  
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